April 17 (Reuters) – Eli Lilly’s newly launched obesity pill was prescribed 1,390 times in the U.S. as of the week ended April 10, according to an analyst who cited IQVIA data.
Novo Nordisk’s oral Wegovy had hit 3,071 U.S. prescriptions in the first four days after its launch on January 5.
(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)